State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 7,718,628 shares of Arcutis Biotherapeutics Inc common stock, representing 6.1% of the class, as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 7,718,628 shares of Arcutis Biotherapeutics Inc common stock.
  • Percent of class: The reported stake represents 6.1% of the outstanding common stock.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote of 7,399,852 shares, with sole voting power of 0 shares.
  • Shared dispositive power: The filing reports shared power to dispose or direct the disposition of 7,718,628 shares, with sole dispositive power of 0 shares.
  • Subsidiaries involved: Five investment adviser subsidiaries are identified, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.

State Street's Schedule 13G Filing on Arcutis Biotherapeutics Common Stock

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in Arcutis Biotherapeutics Inc (CUSIP 03969K108), a company whose principal executive offices are located at 2945 Townsgate Road Suite 110, Westlake Village, California 91361. The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026, with the triggering event dated September 30, 2026.

According to the filing, State Street reported aggregate beneficial ownership of 7,718,628 shares, equal to 6.1% of the class. The reporting person classified itself as a parent holding company (type "HC") under Item 12. All voting and dispositive power is held on a shared basis: shared voting power covers 7,399,852 shares, while shared dispositive power covers all 7,718,628 shares. The filing reports zero sole voting power and zero sole dispositive power.

The filing identifies five subsidiaries through which the securities were acquired, each classified as an investment adviser (IA): SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. State Street certified, per Item 10 of the Schedule 13G, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 6.1% beneficial ownership stake in Arcutis Biotherapeutics Inc common stock, totaling 7,718,628 shares as of September 30, 2026, held through five investment adviser subsidiaries with all power exercised on a shared basis.